A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Phase 4

Completed

• Conditions: Mild Cognitive Impairment
• Interventions: Drug: placebo; Drug: Aricept (donepezil hydrochloride)

• Registration Number: NCT00934375
• Lead Sponsor: Eisai Inc.

Brief Summary

This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Primary Completion: 2007-09
• Study Completion: 2007-09
• Study First Submitted: 2009-05-14
• Study First Submitted QC: 2009-05-14
• Results First Submitted QC: 2009-05-14
• Study First Posted: 2009-07-08
• Results First Posted: 2009-07-08
• Results First Submitted: 2011-07-25
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-12
• Last Update Posted: 2014-01-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 145

Inclusion Criteria

1. Age Range: Adult subjects (45 to 90 years of age inclusive)
2. Sex distribution: Men and women. Women of child-bearing potential (<1 year post menopausal) must be practicing effective contraception and have negative serum B-HCG at Screening. [Women who are breast-feeding are excluded.]
3. Subjects must have completed the one year, double-blind core trial (E2020-A001-412).
4. A completed Diagnostic Worksheet at the end of the double-blind core trial (E2020-A001-412) indicating no conversion to Alzheimer's Disease or dementia.
5. Health: Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane).
6. The subject must be expected to complete the entire study.
7. Subjects must be sufficiently fluent in English.
8. Subjects must have an informant who has daily contact with the subject (e.g., an average of 10 or more hours per week), can observe for possible adverse events and will accompany the subject to all visits.
9. Clinical laboratory values must be within normal limits, or if abnormal, judged clinically insignificant by the investigator (not likely to cause cognitive impairment or medical instability).

Exclusion Criteria

1. Subjects who have not completed or have terminated early from the one year, double-blind core trial (E2020-A001-412).
2. Any subject without a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412).
3. Any subject with a completed diagnostic worksheet from Week 51 of the core double-blind trial (E2020-A001-412) indicating conversion to Alzheimer's or other dementia.
4. Subjects with uncontrolled hypertension (sitting systolic >= 160mmHg and/or diastolic >=95mmHg) as assessed by the investigator, regardless of whether or not the subject is taking anti-hypertensive medications.
5. Subjects with a history of malignant neoplasms treated within five years prior to study entry (other than basal or squamous cell carcinoma of the skin); current evidence of malignant neoplasm; or recurrent or matastatic disease.
6. Subjects who have suffered a severe infection or a major surgical procedure within three months prior to baseline.
7. Subjects who may not be able to comply with the protocol.
8. Subjects with known hypersensitivity to piperidine derivatives or acetylcholinesterase(AChE)inhibitors.
9. Subjects with diabetes mellitis not controlled by diet and/or medication with a random serum glucose value of >170mg/dl.
10. Any condition which would make the subject, in the opinion of the investigator, unsuitable for the study.
11. Subjects who do not have a reliable informant (e.g., the informant has contact with the subject less than 10 hours per week).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	placebo	-
1	Aricept (donepezil hydrochloride)	-

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment-Emergent Adverse Events	Baseline, Week 6, Week 12 and Week 28.	Overview of Treatment-Emergent Adverse Events and Safety Population (TEAEs)

Trial Locations

Locations (47)

Neurology Neurodiagnostic Lab, LLC; 🇺🇸 Alabaster, Alabama, United States

Pivotal Research Centers; 🇺🇸 Peoria, Arizona, United States

Sun Health Research Institute; 🇺🇸 Sun City, Arizona, United States

Northwest Neurospecialists, PLLC; 🇺🇸 Tucson, Arizona, United States

The Neurology Center; 🇺🇸 Encinitas, California, United States

Margolin Brain Institute; 🇺🇸 Fresno, California, United States

Colaborative Neuroscience Network (CNS Network); 🇺🇸 Garden Grove, California, United States

Nerve Pro Research; 🇺🇸 Irvine, California, United States

Optimum Health Services; 🇺🇸 La Mesa, California, United States

Pacific Research Network; 🇺🇸 Vista, California, United States

Scroll for more (37 remaining)